{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:54:25Z","timestamp":1793894065068,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T00:00:00Z","timestamp":1255046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-230x-9-75","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T18:14:23Z","timestamp":1255112063000},"source":"Crossref","is-referenced-by-count":20,"title":["Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology"],"prefix":"10.1186","volume":"9","author":[{"given":"Norberto C","family":"Chavez-Tapia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix I","family":"Tellez-Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Bedogni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lory S","family":"Croc\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Masutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,9]]},"reference":[{"issue":"8","key":"367_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/archinte.167.8.774","volume":"167","author":"S Al Snih","year":"2007","unstructured":"Al Snih S, Ottenbacher KJ, Markides KS, Kuo YF, Eschbach K, Goodwin JS: The effect of obesity on disability vs mortality in older Americans. Archives of internal medicine. 2007, 167 (8): 774-780. 10.1001\/archinte.167.8.774.","journal-title":"Archives of internal medicine"},{"issue":"8","key":"367_CR2","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJMoa055643","volume":"355","author":"KF Adams","year":"2006","unstructured":"Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF: Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. The New England journal of medicine. 2006, 355 (8): 763-778. 10.1056\/NEJMoa055643.","journal-title":"The New England journal of medicine"},{"issue":"2","key":"367_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.atherosclerosis.2006.02.019","volume":"190","author":"MR Skilton","year":"2007","unstructured":"Skilton MR, Moulin P, Serusclat A, Nony P, Bonnet F: A comparison of the NCEP-ATPIII, IDF and AHA\/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis. 2007, 190 (2): 416-422. 10.1016\/j.atherosclerosis.2006.02.019.","journal-title":"Atherosclerosis"},{"issue":"8","key":"367_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1503\/cmaj.061409","volume":"176","author":"DC Lau","year":"2007","unstructured":"Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E: 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. Cmaj. 2007, 176 (8): S1-13.","journal-title":"Cmaj"},{"issue":"10A","key":"367_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1017\/S1368980007000717","volume":"10","author":"MA Rubio","year":"2007","unstructured":"Rubio MA, Gargallo M, Isabel Millan A, Moreno B: Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public health nutrition. 2007, 10 (10A): 1200-1205. 10.1017\/S1368980007000717.","journal-title":"Public health nutrition"},{"issue":"Suppl 2","key":"367_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-2036.2005.02592.x","volume":"22","author":"P Loria","year":"2005","unstructured":"Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, Rudilosso A, Ballestri S, Carulli N: Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics. 2005, 22 (Suppl 2): 31-36. 10.1111\/j.1365-2036.2005.02592.x.","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"3","key":"367_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.2337\/dc07-1526","volume":"31","author":"G Musso","year":"2008","unstructured":"Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, Cassader M: Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes care. 2008, 31 (3): 562-568. 10.2337\/dc07-1526.","journal-title":"Diabetes care"},{"issue":"2","key":"367_CR8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1665-2681(19)31873-3","volume":"7","author":"E Bugianesi","year":"2008","unstructured":"Bugianesi E, Bellentani S, Tiribelli C, Svegliati Baroni G, Croce LS, Gastaldelli A, Marchesini G, Perseghin G, Tell G: Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Annals of Hepatology. 2008, 7 (2): 157-160.","journal-title":"Annals of Hepatology"},{"issue":"2","key":"367_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmed.2007.12.003","volume":"14","author":"F Marra","year":"2008","unstructured":"Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends in molecular medicine. 2008, 14 (2): 72-81. 10.1016\/j.molmed.2007.12.003.","journal-title":"Trends in molecular medicine"},{"issue":"Suppl 2","key":"367_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2036.2005.02593.x","volume":"22","author":"G Marchesini","year":"2005","unstructured":"Marchesini G, Natale S, Manini R, Agostini F: Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Alimentary pharmacology & therapeutics. 2005, 22 (Suppl 2): 37-39. 10.1111\/j.1365-2036.2005.02593.x.","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"2","key":"367_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1464-5491.2007.02332.x","volume":"25","author":"G Zhao","year":"2008","unstructured":"Zhao G, Ford ES, Li C, Mokdad AH: Compliance with physical activity recommendations in US adults with diabetes. Diabet Med. 2008, 25 (2): 221-227. 10.1111\/j.1464-5491.2007.02332.x.","journal-title":"Diabet Med"},{"issue":"2","key":"367_CR12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hep.22009","volume":"47","author":"S Bellentani","year":"2008","unstructured":"Bellentani S, Dalle Grave R, Suppini A, Marchesini G: Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology (Baltimore, Md). 2008, 47 (2): 746-754. 10.1002\/hep.22009.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"3","key":"367_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","volume":"29","author":"JP Despres","year":"2009","unstructured":"Despres JP, Ross R, Boka G, Almeras N, Lemieux I: Effect of rimonabant on the high-triglyceride\/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arteriosclerosis, thrombosis, and vascular biology. 2009, 29 (3): 416-423. 10.1161\/ATVBAHA.108.176362.","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"key":"367_CR14","unstructured":"An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes. [ http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00577148?term=fatty+liver&rank=39 ]"},{"key":"367_CR15","unstructured":"An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes. [ http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00576667?term=fatty+liver&rank=40 ]"},{"issue":"8","key":"367_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/j.1478-3231.2007.01555.x","volume":"27","author":"M Banasch","year":"2007","unstructured":"Banasch M, Goetze O, Schmidt WE, Meier JJ: Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver Int. 2007, 27 (8): 1152-1155. 10.1111\/j.1478-3231.2007.01555.x.","journal-title":"Liver Int"},{"issue":"4","key":"367_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1055\/s-0028-1091984","volume":"28","author":"MR Kashi","year":"2008","unstructured":"Kashi MR, Torres DM, Harrison SA: Current and emerging therapies in nonalcoholic fatty liver disease. Seminars in liver disease. 2008, 28 (4): 396-406. 10.1055\/s-0028-1091984.","journal-title":"Seminars in liver disease"},{"issue":"9600","key":"367_CR18","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007, 370 (9600): 1706-1713. 10.1016\/S0140-6736(07)61721-8.","journal-title":"Lancet"},{"key":"367_CR19","doi-asserted-by":"crossref","unstructured":"Curioni C, Andre C: Rimonabant for overweight or obesity. Cochrane database of systematic reviews (Online). 2006, CD006162-4","DOI":"10.1002\/14651858.CD006162"},{"key":"367_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2288-8-22","volume":"8","author":"A Lundh","year":"2008","unstructured":"Lundh A, Gotzsche PC: Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC medical research methodology. 2008, 8: 22-10.1186\/1471-2288-8-22.","journal-title":"BMC medical research methodology"},{"key":"367_CR21","volume-title":"Version 5 for Windows edn","author":"TNC Centre","year":"2008","unstructured":"Centre TNC: Review Manager (RevMan). Version 5 for Windows edn. 2008, Copenhagen: The Cochrane Collaboration"},{"issue":"11","key":"367_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002, 21 (11): 1539-1558. 10.1002\/sim.1186.","journal-title":"Statistics in medicine"},{"issue":"7109","key":"367_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997, 315 (7109): 629-634.","journal-title":"BMJ (Clinical research ed)"},{"issue":"9468","key":"367_CR24","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005, 365 (9468): 1389-1397. 10.1016\/S0140-6736(05)66374-X.","journal-title":"Lancet"},{"issue":"7","key":"367_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. Jama. 2006, 295 (7): 761-775. 10.1001\/jama.295.7.761.","journal-title":"Jama"},{"issue":"20","key":"367_CR26","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"JP Despres","year":"2005","unstructured":"Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England journal of medicine. 2005, 353 (20): 2121-2134. 10.1056\/NEJMoa044537.","journal-title":"The New England journal of medicine"},{"issue":"9548","key":"367_CR27","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"AJ Scheen","year":"2006","unstructured":"Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006, 368 (9548): 1660-1672. 10.1016\/S0140-6736(06)69571-8.","journal-title":"Lancet"},{"issue":"13","key":"367_CR28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, et al: Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. Jama. 2008, 299 (13): 1547-1560. 10.1001\/jama.299.13.1547.","journal-title":"Jama"},{"issue":"Suppl 2","key":"367_CR29","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.2337\/dc08-s258","volume":"31","author":"L Van Gaal","year":"2008","unstructured":"Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A: Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes care. 2008, 31 (Suppl 2): S229-240. 10.2337\/dc08-s258.","journal-title":"Diabetes care"},{"issue":"3","key":"367_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JCP.0b013e318172b8bc","volume":"28","author":"M Soyka","year":"2008","unstructured":"Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF: Cannabinoid Receptor 1 Blocker Rimonabant (SR 141716) for Treatment of Alcohol Dependence: Results From a Placebo-Controlled, Double-Blind Trial. Journal of clinical psychopharmacology. 2008, 28 (3): 317-324. 10.1097\/JCP.0b013e318172b8bc.","journal-title":"Journal of clinical psychopharmacology"},{"issue":"6","key":"367_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1365-2265.2008.03260.x","volume":"69","author":"T Sathyapalan","year":"2008","unstructured":"Sathyapalan T, Cho L, Kilpatrick ES, Coady AM, Atkin SL: A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome: a randomised open labelled parallel study. Clinical endocrinology. 2008, 69 (6): 931-5. 10.1111\/j.1365-2265.2008.03260.x.","journal-title":"Clinical endocrinology"},{"issue":"11","key":"367_CR32","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2337\/dc08-0386","volume":"31","author":"J Rosenstock","year":"2008","unstructured":"Rosenstock J, Hollander P, Chevalier S, Iranmanesh A: The SERENADE Trial: Effects of Monotherapy with Rimonabant, the First Selective CB1 Receptor Antagonist, on Glycemic Control, Body Weight and Lipid Profile in Drug-naive Type 2 Diabetes. Diabetes care. 2008, 31 (11): 2169-76. 10.2337\/dc08-0386.","journal-title":"Diabetes care"},{"issue":"5","key":"367_CR33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1467-789X.2009.00581.x","volume":"10","author":"K Johansson","year":"2009","unstructured":"Johansson K, Neovius K, Desantis SM, Rossner S, Neovius M: Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009, 10 (5): 564-75. 10.1111\/j.1467-789X.2009.00581.x.","journal-title":"Obes Rev"},{"issue":"2","key":"367_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jhep.2008.05.003","volume":"49","author":"S Bellentani","year":"2008","unstructured":"Bellentani S, Bedogni G, Tiribelli C: Liver and heart: a new link?. Journal of hepatology. 2008, 49 (2): 300-302. 10.1016\/j.jhep.2008.05.003.","journal-title":"Journal of hepatology"},{"issue":"8","key":"367_CR35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1503\/cmaj.070306","volume":"176","author":"DC Lau","year":"2007","unstructured":"Lau DC: Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. Cmaj. 2007, 176 (8): 1103-1106.","journal-title":"Cmaj"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-230X-9-75\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-9-75.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-9-75","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-9-75.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T22:46:57Z","timestamp":1590187617000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/1471-230X-9-75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1186\/1471-230x-9-75","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,9]]},"article-number":"75"}}